RxDoctor Payments Data

Fariha Abbasi-Feinberg, MD

Sleep Medicine · Fort Myers, FLNPI 1295721868

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 28.8% of the total.

$5,641in general payments, 2019–2025

Across 195 payments — averaging $28.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$2K
  • Harmony Biosciences LLC$1K
  • Inspire Medical Systems, Inc.$736
  • Lilly USA, LLC$247
  • Xeris Pharmaceuticals, Inc.$168
  • Vanda Pharmaceuticals Inc.$161
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$5,37195%
  • Education$2705%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,641 in reported general payments places this provider in the 70th percentile of 77 sleep medicine providers in Florida.

See all sleep medicine providers in Florida

Medicare billing

Part B allowed, 2024
$161,007
Medicare patients
837
Services billed
1,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl14$195,079
Modafinil41$5,018
DayvigoLemborexant11$3,649
Gabapentin185$2,084
Doxepin Hcl28$1,195
Armodafinil29$1,160
Clonazepam133$632
Eszopiclone17$445
Zolpidem Tartrate65$427
Ropinirole Hcl13$412
Temazepam14$139
Trazodone Hcl14$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$1,291$195,07914 claims
Eisai Inc.Dayvigo$19$3,64911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 77 sleep medicine providers in Florida.

Other sleep medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →